<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846166</url>
  </required_header>
  <id_info>
    <org_study_id>B-1921</org_study_id>
    <nct_id>NCT04846166</nct_id>
  </id_info>
  <brief_title>I-Smads in Periodontitis</brief_title>
  <official_title>Role of Inhibitor SMADs in Stage 3 Grade B Periodontitis Before and After Periodontal Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bulent Ecevit University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bulent Ecevit University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, it has been stated that Smads play an active role in all conditions where&#xD;
      transforming growth factor-beta (TGF-β) is involved, including periodontal inflammation. This&#xD;
      study aimed to examine the levels of TGF-β and inhibitor Smads in saliva and gingival&#xD;
      crevicular fluid (GCF) in patients with Stage 3 Grade B periodontitis before and after&#xD;
      non-surgical periodontal treatment. Twenty (20) stage 3 grade B periodontitis and 20&#xD;
      periodontally healthy individuals were included in the study. Clinical periodontal&#xD;
      measurements were recorded; periodontitis patients received non-surgical periodontal&#xD;
      treatment, and GCF and saliva samples were obtained at baseline and one month after&#xD;
      treatment. TGF-β, Smad6, and Smad7 were determined by ELISA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>TGF-β, Smad6, and Smad7 levels</measure>
    <time_frame>baseline</time_frame>
    <description>the levels of TGF-β, Smad6, and Smad7 in gingival crevicular fluid (GCF) and saliva</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TGF-β, Smad6, and Smad7 levels</measure>
    <time_frame>baseline and 1st month after treatment</time_frame>
    <description>the levels of TGF-β, Smad6, and Smad7 in gingival crevicular fluid (GCF) and saliva before and after non-surgical periodontal treatment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Periodontitis</condition>
  <condition>Treatment Adherence</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Periodontitis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Periodontally healthy group</intervention_name>
    <description>probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) &lt; 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Periodontitis</intervention_name>
    <description>: interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth</description>
    <arm_group_label>Periodontitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. group (Control): Periodontally and systemically healthy&#xD;
&#xD;
          2. group: Systemically healthy and periodontitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have at least 20 natural teeth, excluding third molars.&#xD;
&#xD;
          -  Periodontitis patients had at least two non-adjacent sites per quadrant with probing&#xD;
             depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival&#xD;
             inflammation, and alveolar bone loss affecting &gt;30% of the teeth, as detected on&#xD;
             clinical and radiographical examinations.&#xD;
&#xD;
          -  Periodontally healthy control group had no sign of gingival inflammation, no PD &gt; 3mm&#xD;
             and no evidence of attachment or bone loss&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of systemic disease.&#xD;
&#xD;
          -  Regular use of any drugs which can effect the immune system or inflammatory response&#xD;
             in the 6 months preceding the start of the study.&#xD;
&#xD;
          -  Periodontal treatment during last 6 months that could affect periodontal status.&#xD;
&#xD;
          -  Smoking.&#xD;
&#xD;
          -  History of radiotherapy or chemotherapy.&#xD;
&#xD;
          -  Current pregnancy, lactation or menopause.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Figen Öngöz Dede</name>
      <address>
        <city>Ordu</city>
        <zip>52100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bulent Ecevit University</investigator_affiliation>
    <investigator_full_name>Figen Öngöz Dede</investigator_full_name>
    <investigator_title>T.C. ORDU ÜNİVERSİTESİ</investigator_title>
  </responsible_party>
  <keyword>Smad</keyword>
  <keyword>Periodontitis</keyword>
  <keyword>Gingival crevicular fluid</keyword>
  <keyword>Saliva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

